Company news
Avalon GloboCare Corp. news in 2022
Avalon GloboCare Corp.'s news releases, calls and decks from 2022, newest first.
Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services
December 13, 2022
Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC
December 11, 2022
Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”
November 8, 2022
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
November 7, 2022
Avalon GloboCare Receives Allowance for Joint U.S. Patent
September 28, 2022
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
August 7, 2022
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
June 29, 2022
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
May 17, 2022
Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
April 26, 2022
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
February 13, 2022
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
January 3, 2022
Decks in 2022
- Investor Presentation (May 2022)
Investor deck · 24 slides · May 2, 2022